Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL3369680 | 0.97 | TSHR (0.50) | TSHRTHRBLMNASLC22A1DNM1 | |
| Hexane SCHEMBL7875362 | 0.97 | TSHR (0.47) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Heptane SCHEMBL7940831 | 0.93 | TSHR (0.53) | TSHRTHRBLMNASLC22A1DNM1 | |
| Undecane SCHEMBL28267168 | 0.93 | TSHR (0.53) | TSHRTHRBLMNASLC22A1DNM1 | |
| Octane SCHEMBL20299932 | 0.93 | TSHR (0.53) | TSHRTHRBLMNASLC22A1DNM1 | |
| Pentane SCHEMBL12271939 | 0.93 | TSHR (0.47) | TSHRTHRBLMNAALDH1A1 | |
| Dodecane SCHEMBL20299936 | 0.93 | TSHR (0.53) | TSHRTHRBLMNASLC22A1DNM1 | |
| Butane SCHEMBL3799640 | 0.82 | TSHR (0.33) | TSHRALDH1A1 | |
| Water SCHEMBL28300553 | 0.81 | TSHR (0.57) | TSHRTHRBALDH1A1 | |
| SCHEMBL20913050 | 0.79 | TSHR (0.52) | TSHRTHRBLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962606-B2 | Substituted benzosulphonamides | BAYER INTELLECTUAL PROPERTY GMBH (US) | 2015-02-24 | — | — | US | disclosed |
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120269804-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120269803-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| EP-2491016-A1 | SUBSTITUTED BENZOSULPHONAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491015-A1 | SUBSTITUTED BENZOSULPHONAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011047788-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011047795-A1 | SUBSTITUTED BENZOSULPHONAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-28 | — | — | WO | disclosed |
| US-7846956-B2 | Malononitrile compound as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-12-07 | — | — | US | disclosed |
| EP-1411761-B1 | METABOLITE TRANSPORTERS | MONSANTO TECHNOLOGY LLC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20020069426-A1 | Methyl-D-erythritol phosphate pathway genes | MONSANTO TECHNOLOGY, L.L.C. | 2002-06-06 | — | — | US | disclosed |
| EP-1171122-A4 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2002-05-29 | — | — | EP | disclosed |
| US-20020049257-A1 | Antibacterial composition | GIVAUDAN SA (CH) | 2002-04-25 | — | — | US | disclosed |
| WO-2002012478-A2 | METHYL-D-ERYTHRITOL PHOSPHATE PATHWAY GENES | MONSANTO TECHNOLOGY, LLC (US) | 2002-02-14 | — | — | WO | disclosed |
| EP-1171122-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| US-6200985-B1 | ADMINISTERING TO PREVENT ORGAN OR TISSUE TRANSPLANT REJECTION | NOVARTIS AG (CH) | 2001-03-13 | — | — | US | disclosed |
| WO-2000059502-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| US-5985890-A | Rapamycin derivatives | NOVARTIS AG (CH) | 1999-11-16 | — | — | US | disclosed |
| EP-0833828-A1 | RAPAMYCIN DERIVATIVES | Novartis AG (CH) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996041807-A1 | RAPAMYCIN DERIVATIVES | NOVARTIS AG (CH) | 1996-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049257-A1 | Antibacterial composition | LPO, C5, PYM1 | TSHR 1456/4885THRB 984/4885LMNA 4487/4885 |
| US-20120269803-A1 | SUBSTITUTED BENZOSULPHONAMIDES | VEGFA, CCND2, F12 | TSHR 2654/4885THRB 3166/4885LMNA 2131/4885 |
| US-20120269804-A1 | SUBSTITUTED BENZOSULPHONAMIDES | VEGFA, CCND2, F12 | TSHR 2654/4885THRB 3166/4885LMNA 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.